Navigation Links
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Date:12/6/2016

SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus' wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. The financial terms were not disclosed.

"Given Takeda's long-standing commitment to and expertise in GI disorders, we are confident we have found an ideal partner to accelerate and maximize the potential of our LUNAR and UNA technology platforms toward the development of novel RNA therapeutics for the treatment of NASH," said Dr. Pad Chivukula, CSO & COO of Arcturus Therapeutics, Inc. "This agreement underscores Arcturus' ability to rapidly discover, design and optimize RNA medicines in areas of unmet need." 

About Arcturus Therapeutics, Inc.   

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S., Europe, Japan and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Ultragenyx Pharmaceutical, Inc. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arcturus-therapeutics-announces-collaboration-with-takeda-pharmaceuticals-to-develop-rna-based-therapeutics-for-the-treatment-of-nonalcoholic-steatohepatitis-nash-300373830.html


'/>"/>
SOURCE Arcturus Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
2. Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
3. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
4. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
5. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
6. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
7. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
8. Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
9. Mission Therapeutics Appoints Colin Goddard as Chairman
10. Research Reports Initiation on Healthcare Stocks -- NuVasive, Smith & Nephew, Nxstage Medical, and Cesca Therapeutics
11. Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
Breaking Medicine News(10 mins):